Glenmark says specialty & innovative products to contribute 30% revenues by 2025

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Drug maker Glenmark Pharmaceuticals on Friday said the company as part of a strategic blue print for the next decade plans to transition from being a pure generics-driven company to being an organization built on three pillars -- global generics, specialty products and innovative products.

Glemark said it hopes to generate 30 percent of its revenues by 2025 from specialty and innovative products alone.

To invest on specialty and innovative pipeline Glenmark said its R&D expenses will stay at roughly 11–12 percent of revenues.

“Generics will continue to be the engine of our growth over the next five years,” said Glenn Saldanha, Chairman and Managing Director of Glenmark in his speech at the company’s 39th annual general meeting on Friday.

“We want to build a robust business in our key markets such as India, US and Europe,” Saldanha added.

Saldanha said another key growth driver will be specialty products which will help the company to move up the value chain to branded products in highly regulated markets especially US.

“This will enable us to build a sustainable revenue stream against price erosion of generics,” he said.

Saldanha said he expects steady improvement of profitability margins from 22 percent to 25 percent by 2025.

Presently, Glenmark has three programs for specialty products in the pipeline for US that includes GSP301, an intranasal spray for allergic rhinitis which has completed phase-3 trials and is preparing to file its first ever NDA next year. The other programmes GSP 304 indicated for the treatment of COPD is currently in Phase 2 and GBR 310 which is a biosimilar for Xolair or Omalizumab currently phase-1. Xolair is used in treatment of asthma.

Glenmark, which has been investing on drug discovery for years, said its lead molecule GBR 830, an OX 40 antagonist, indicated for atopic dermatitis has completed phase 2a study.

“We are exploring the development of GBR830 in other auto immune diseases,” Saldanha. Glenmark has earlier indicated that it’s looking for out-licensing to take the further development, regulatory filings and commercialization of the drug.